Rapt Therapeutics Inc Reports Results For The Quarter Ended September 30: Earnings Summary
12/11/2024 15:27
* RAPT Therapeutics Inc RAPT.OQ reported a quarterly
adjusted
loss of 47 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -82 cents. The mean expectation of ten analysts
for the quarter was for a loss of 56 cents per share. Wall
Street expected results to range from -64 cents to -37 cents per
share.
* Reported revenue was zero; analysts expected zero.
* RAPT Therapeutics Inc's reported EPS for the quarter was a
loss
of 47 cents.
* The company reported a quarterly loss of $18.43 million.
* RAPT Therapeutics Inc shares had fallen by 12.9% this
quarter and lost 93.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 8
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for RAPT Therapeutics
Inc is $3.00
This summary was machine generated from LSEG data November 12 at
03:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.56 -0.47 Beat
Jun. 30 2024 -0.72 -0.71 Beat
Mar. 31 2024 -0.81 -0.79 Beat
Dec. 31 2023 -0.86 -0.80 Beat